Top Markets
Coin of the day
Algernon Pharmaceuticals Inc. Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals Inc.

AGN
Rankning i aktier #38375
Algernon Pharmaceuticals Inc. is a clinical-stage pharmaceutical company... Algernon Pharmaceuticals Inc. is a clinical-stage pharmaceutical company dedicated to discovering and developing new treatments. Their research and development efforts concentrate on a range of serious conditions, including non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19, operating across Canada and Australia. The company's primary drug candidate, NP-120, acts as an N-methyl-d-aspartate (NMDA) receptor glutamate antagonist. This compound specifically targets the NMDA-type subunit 2B (Glu2NB) and also demonstrates agonist activity for the Sigma-1 receptor, a chaperone protein elevated during endoplasmic reticulum stress. Furthermore, Algernon is advancing AP-188, a psychedelic agent from the tryptamine family, for treating ischemic stroke in humans. Preclinical investigations for AP-188, as part of their stroke clinical research program, are underway through a collaboration with Charles River Laboratories. Established in 2015, Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.
Aktiekurs
$0.29357476
Senast synkroniserad: 2026-05-14
Marknadsvärde
$1.02M
Förändring (1 dag)
1.27%
Förändring (1 år)
-42.07%
Land
CA
Handel Algernon Pharmaceuticals Inc. (AGN)

Kategori

EPS för Algernon Pharmaceuticals Inc. (AGN)
EPS per 2026 TTM: 0
Enligt Algernon Pharmaceuticals Inc.s senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) 0. Vid slutet av 2026 hade bolaget ett EPS på 0, lika med EPS från 2026 som var 0.
EPS-historik för Algernon Pharmaceuticals Inc. från 2026 till 2026
EPS vid slutet av varje år
År EPS Ändra
Inte tillräckligt med data för de angivna datumen.
EPS för liknande företag eller konkurrenter